Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSB-1216
- Development stage
- Unknown
- Lead developer
- Hillstream BioPharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Injected
01
Overview
HSB-1216 is a novel formulation of salinomycin, a potent cancer stem cell inhibitor, encapsulated in Hillstream BioPharma's proprietary QUATRAMER delivery technology. It targets cancer stem cells by inducing ferroptosis, a form of iron-mediated cell death. HSB-1216 is being developed for the treatment of various solid tumors, including small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and uveal melanoma.
- Other names
- Salinomycin
Beyond the preview
Go deeper on HSB-1216.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSB-1216.